Indications for: VISIPAQUE 320
Intra-arterial: Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. IV: CECT imaging of the head and body, and excretory urography.
Usual single doses: Intra-arterial: Arteriography: Carotid arteries: 10–14mL; Vertebral arteries: 10–12mL (max 175mL); Right coronary artery: 3–8mL; Left coronary artery: 3–10mL; Left ventricle: 20–45mL (max 200mL); Renal arteries: 8–18mL; Aortography: 30–70mL; Major branches of aorta: 10–70mL; Aortofemoral runoffs: 20–90mL; Peripheral arteries: 15–30mL (max 250mL). Intra-arterial Digital Subtraction Angiography: Carotid or vertebral arteries: 5–8mL (max 175mL); Aortography: 10–50mL; Major branches of aorta: 2–10mL; Aortofemoral runoffs: 6–15mL; Peripheral arteries: 3–15mL (max 250mL). IV: CECT of head or body: 75–150mL bolus or 100–150mL infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL.
<1yr: not recommended. ≥1yr: Intra-arterial for cerebral, cardiac chambers and related major arteries, and visceral studies: 1–2mL/kg; max 4mL/kg.
VISIPAQUE 320 Contraindications:
Intrathecal use. Children: Prolonged fasting and laxative administration before Visipaque injection.
VISIPAQUE 320 Warnings/Precautions:
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune deficiency disorder. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
VISIPAQUE 320 Classification:
Radiographic contrast medium.
VISIPAQUE 320 Interactions:
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Rash, erythema, pruritus, scotoma; thromboembolic events, hypersensitivity reactions, others.